We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Value Investors Now Choose Bristol Myers (BMY) Stock?
Read MoreHide Full Article
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Bristol Myers Squibb Company (BMY - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Bristol Myers Squibb has a trailing twelve months PE ratio of 10.4, as you can see in the chart below:
This level actually compares favorably with the market at large, as the PE for the S&P 500 stands at about 26.21. If we focus on the long-term PE trend, Bristol Myers Squibb’s current PE level puts it below its midpoint over the past five years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.
However, the stock’s PE also compares unfavorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 25.32. At the very least, this indicates that the stock is slightly undervalued right now, compared to its peers.
We should also point out that Bristol Myers Squibb has a forward PE ratio (price relative to this year’s earnings) of just 10.04, so it is fair to say that a slightly more value-oriented path may be ahead for Bristol Myers Squibb’s stock in the near term too.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Bristol Myers Squibb has a P/S ratio of about 3.75. This is lower than the S&P 500 average, which comes in at 4.6 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.
Broad Value Outlook
In aggregate, Bristol Myers Squibb currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Bristol Myers Squibb a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for Bristol Myers Squibb is just 1.10, a level that is lower than the industry average of 1.46. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 14.49, which is better than the industry average of 16.84. Clearly, BMY is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Bristol Myers Squibb might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of A and Momentum Score of C. This gives Bristol Myers Squibb a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been mixed, at the best. The current quarter has seen one upward revision in the past sixty days compared to three downward revisions, while the current year estimate has seen seven upward revisions compared to no downward revision in the same time period.
This has had a noticeable impact on the consensus estimate, as the current quarter consensus estimate declined 2.9% in the past two months, whereas the current year estimate increased 1.6% in the past two months. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Owing to mixed estimate trends, the stock has a Zacks Rank #3 (Hold), which is why we are looking for in-line performance from the company in the near term.
Bottom Line
Bristol Myers Squibb is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the sector has clearly underperformed the market at large, as you can see below:
So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Shutterstock
Should Value Investors Now Choose Bristol Myers (BMY) Stock?
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Bristol Myers Squibb Company (BMY - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Bristol Myers Squibb has a trailing twelve months PE ratio of 10.4, as you can see in the chart below:
This level actually compares favorably with the market at large, as the PE for the S&P 500 stands at about 26.21. If we focus on the long-term PE trend, Bristol Myers Squibb’s current PE level puts it below its midpoint over the past five years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.
However, the stock’s PE also compares unfavorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 25.32. At the very least, this indicates that the stock is slightly undervalued right now, compared to its peers.
We should also point out that Bristol Myers Squibb has a forward PE ratio (price relative to this year’s earnings) of just 10.04, so it is fair to say that a slightly more value-oriented path may be ahead for Bristol Myers Squibb’s stock in the near term too.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Bristol Myers Squibb has a P/S ratio of about 3.75. This is lower than the S&P 500 average, which comes in at 4.6 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.
Broad Value Outlook
In aggregate, Bristol Myers Squibb currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Bristol Myers Squibb a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for Bristol Myers Squibb is just 1.10, a level that is lower than the industry average of 1.46. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 14.49, which is better than the industry average of 16.84. Clearly, BMY is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Bristol Myers Squibb might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of A and Momentum Score of C. This gives Bristol Myers Squibb a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been mixed, at the best. The current quarter has seen one upward revision in the past sixty days compared to three downward revisions, while the current year estimate has seen seven upward revisions compared to no downward revision in the same time period.
This has had a noticeable impact on the consensus estimate, as the current quarter consensus estimate declined 2.9% in the past two months, whereas the current year estimate increased 1.6% in the past two months. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Bristol Myers Squibb Company Price and Consensus
Bristol Myers Squibb Company price-consensus-chart | Bristol Myers Squibb Company Quote
Owing to mixed estimate trends, the stock has a Zacks Rank #3 (Hold), which is why we are looking for in-line performance from the company in the near term.
Bottom Line
Bristol Myers Squibb is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the sector has clearly underperformed the market at large, as you can see below:
So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>